Percutaneous Needle Aspiration of a Partially Deflated Intragastric Balloon: a Forgotten Modality? Review of the Literature
To the editors,
It is estimated that more than 300,000 intragastric balloons (IGBs) have been successfully used for weight loss for the last 30 years. Balloon deflation is among the complications reported in the literature and ranges from 3.2 to 3.4% [1, 2]. A fluid-filled IGB is customarily injected with 2–5 ml of a 1% solution of methylene blue such that deflation results in absorption of the methylene blue and its excretion in the urine. This causes a bluish discoloration of the urine and alerts the patient to the deflation. The deflated balloon can either stay in the stomach for a period of time from which it is removed by the endoscopist, or it can migrate into the intestines and pass into the stool with or without symptoms of nausea and pain along the way. In rare circumstances, the migrated IGB impacts the small bowel with a resultant small bowel obstruction (SBO). In her review of 17 IGB publications, Mathus-Vliegen reported a 3.2% (132/4037) incidence of BioEnterics...
Compliance with Ethical Standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of Interest
Dr Jeffrey Brooks is a shareholder and a patent holder at Spatz FGIA Inc and has reported this in his COI form. Dr’s Rimon, BenSaid, Lang, Nadler, Schwartz, and BarMeir have no conflict of interest to report as documented in their individual COI forms.
Informed consent was obtained from the patient in this report for all the performed procedures.